• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Galera adds $15m for Series B

November 28, 2016 By Sarah Faulkner

Galera adds $15m for Series BGalera Therapeutics said today that it landed $15 million for its severe oral mucositis treatment, bringing its Series B financing total to $57 million. Sofinnova Ventures led the round, joining existing investors New Enterprise Associates, Novartis Venture Fund, Novo Ventures, Correlation Ventures, Enso Ventures and Galera Angels.

The Malvern, Penn.-based company said the proceeds will be used to prepare its lead candidate for phase III registration studies. The treatment, GC4419, is in a randomized, placebo-controlled phase IIb clinical trial to study its impact on severe oral mucositis in head and neck cancer patients undergoing chemo-radiation therapy. The funds will also be used to fund the development of its pipeline of selective dismutase mimetics.

“This investment by Sofinnova is a further endorsement of Galera’s team, technology and clinical data generated to date, and of the promise of our dismutase mimetics to transform cancer treatment,” Galera president & CEO Dr. J. Mel Sorensen said in prepared remarks. “We look forward to expanding our development programs and demonstrating the utility of our technology in treating patients with cancer.”

“Sofinnova Ventures has been intrigued for some time in Galera’s scientific approach and thoughtful clinical development program,” Sofinnova general partner Mike Powell added. Galera also said that Powell will join the company’s Board of Directors. “I am personally excited to support Galera and work with Mel Sorensen and his team again.”

“We are very pleased to welcome Mike to our Board of Directors,” Dr. Sorensen said. “His experience and long history of success in biotech is well known and we look forward to his advice and input on our technology and development programs.”

Filed Under: Clinical Trials, Featured, Funding Roundup, Oncology Tagged With: Galera Therapeutics

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS